3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Polycystic Ovary Syndrome
9
Motor Activity
7
Prostatic Neoplasms
3
Colorectal Neoplasms
2
Urinary Bladder Neoplasms
1
Rectal Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms
1
Multiple Endocrine Neoplasia Type 1
1
Lymphoma, Follicular
1
Lupus Erythematosus, Systemic
1
Insulin Resistance
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Fatigue
1
Diabetes Mellitus, Type 1
1
Cardiovascular Diseases
1
Cardiotoxicity
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Arthritis, Rheumatoid
1
Anxiety Disorders
1
Interventions
Mitomycin
11
Gemcitabine
7
BCG Vaccine
4
Imiquimod
2
Administration, Intravesical
2
viscum album peptide
1
pemigatinib
1
pembrolizumab
1
erdafitinib
1
dodecyl maltoside
1
Water
1
VPM1002 recombinant BCG vaccine
1
VB4-845
1
Therapeutics
1
Photochemotherapy
1
Neoadjuvant Therapy
1
Interferon-alpha
1
Hyaluronic Acid
1
High-Intensity Interval Training
1
Gels
1
Ethacrynic Acid
1
Epirubicin
1
Educational Status
1
Doxorubicin
1
Docetaxel
1
Dihematoporphyrin Ether
1
Cystoscopy
1
Celecoxib
1
BCG Connaught
1
5-aminolevulinic acid hexyl ester
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Non-Muscle Invasive Bladder Neoplasms
×
High-Intensity Interval Training
×
Clear all
NCT04593862
2024-09-19
BRAVE
University of Alberta
Phase 2
Completed
25 enrolled